Engility Holdings Merges with SAIC for $2.5 Billion

We represented Engility Holdings (NYSE: EGL) in its merger with Science Applications International Corp. (NYSE: SAIC) in which SAIC acquired Engility in an all-stock transaction valued at $2.5 billion. With two highly complementary portfolios, the transaction creates market sub-segment scale in strategic business areas of national interest, such as defense, federal civilian agencies, intelligence, and space. In addition, it expands the capabilities of both companies, bringing additional systems engineering, mission, and IT capabilities to a broader base of customers. The combined company ranks as the second largest independent technology integrator in government services.

Engility Holdings, Inc. is a pure-play government services contractor providing highly skilled personnel wherever, whenever they are needed in a cost-effective manner.

SAIC is a premier technology integrator providing full life cycle services and solutions in the technical, engineering, intelligence, and enterprise information technology markets.

This transaction was named a winner in the “Industrials Deal of the Year (Over $1B),” category for the 18th Annual M&A Advisor Awards in 2019. In addition, it had been named a finalist in the “Corporate/Strategic Deal of the Year ($1B-$5B)” and “Private Equity Deal of the Year (Over $1B)” categories. Bass, Berry & Sims had six separate deals recognized as finalists among nine categories for the 2019 M&A Advisor Awards.

You Also May Be Interested In:

  • We represented ALS Education, Inc., an education dropout prevention and recovery program, in the sale of its charter school management...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company
  • Representation of NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and investment funds managed by Morgan Stanley Tactical Value providing a $50 million asset-based credit line (ABL), a 5.5-year $150 million term loan, and a $65 million preferred stock issuance, respectively. Proceeds from the transaction will be used to repay the current principal balance of $70 million on its term loans due in 2022, to redeem its current $100 million outstanding preferred stock, prior to the increase in redemption premium at March 31, 2021, and pay off its fixed interest rate swap of $14 million. The transaction enables the company to strengthen its balance sheet by extending its capital structure’s maturity at an attractive blended cost of capital, allowing the company financial flexibility to continue its current business transformation efforts.

    We represented NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and...
    Client Type: Public Company